RE: ASCO and pharmacometrics
I would echo Pascal’s point. Getting pharmacometric work into large clinical
conferences is not straightforward. It can be done (see link)
http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract but note where I
was in the author list as the sole modeller. It helps to work closely with the
clinicians on the messaging. That said, it was fun at the meeting, explaining
the data and model curves to clinicians with them asking how such knowledge
could impact their patients. An eye-opener. Keep trying Naoto!
All the best, Phil
Philip J Lowe PhD
Executive Director Pharmacometrics Scientist
Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
4056 Basel, Switzerland
Phone: +41 61 324 4676
[email protected]<mailto:[email protected]>
Quoted reply history
From: [email protected] [mailto:[email protected]] On
Behalf Of Pascal Girard
Sent: 06 April 2016 10:39
To: Naoto Hayashi; [email protected]
Cc: nmusers
Subject: RE: [NMusers] ASCO and pharmacometrics
Dear Naoto,
In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is
our ”champion” !
I got one accepted on model for Exp-Tumor Size – OS at European Cancer Congress
2013 . But I can tell you that a medical writer rewrote it entirely and it took
1 month to get it reviewed and corrected by clinicians challenging every comma
and p-value.
To give you an idea of the respective size of the meetings: ACOP N=500, PAGE
N>600, ECC N> 10,000, ASCO N>20,000.
So the advice I would give, is just improve the quality and readability of our
abstract and it will make it. By readability, I mean show it to an oncologist
clinician. If he does not understand, rewrite it with the help of a medical
writer …
With best regards / Mit freundlichen Grüßen / Cordialement
Pascal